Related Experiment Video

Updated: May 1, 2026

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

39.9K

Differential effects of angiotensin II receptor blockers on Aβ generation

Junjun Liu1, Shuyu Liu1, Chiaki Tanabe1

  • 1Department of Neuroscience, School of Pharmacy, Iwate Medical University, 2-1-1 Nishitokuta, Yahaba, Iwate 028-3694, Japan.

Neuroscience Letters
|April 1, 2014
PubMed

Insights

Angiotensin II receptor blockers (ARBs) impact Alzheimer's disease (AD) protein generation differently. Telmisartan increased amyloid-beta (Aβ) production, while other ARBs had varied effects, suggesting distinct roles in AD pathogenesis.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • Angiotensin II receptor blockers (ARBs) are prescribed for hypertension and heart failure.
  • ARBs may reduce Alzheimer's disease (AD) risk and benefit dementia.
  • Amyloid-beta protein (Aβ) is implicated in AD pathogenesis, but ARB effects on Aβ generation are unclear.

Purpose of the Study:

  • To investigate the effects of various ARBs on amyloid-beta (Aβ) generation.
  • To determine if ARBs influence the production of Aβ40 and Aβ42 peptides.
  • To elucidate the molecular pathways involved in ARB-mediated Aβ generation.

Main Methods:

  • Treatment of cells or animal models with different ARBs (telmisartan, losartan, valsartan, candesartan, olmesartan).
  • Quantification of Aβ40 and Aβ42 levels using immunoassays.
  • Analysis of signaling pathways, including angiotensin type 1a receptor (AT1a) and PI3K.

Main Results:

  • Telmisartan significantly increased Aβ40 and Aβ42 generation, lowering the Aβ42/Aβ40 ratio.
  • Losartan, valsartan, and candesartan did not alter Aβ generation.
  • Olmesartan selectively increased Aβ42 generation, and telmisartan's effect was mediated via AT1a and PI3K pathways.

Conclusions:

  • Different ARBs exhibit distinct effects on Aβ generation.
  • Telmisartan promotes Aβ generation through the AT1a and PI3K pathway.
  • Findings suggest a complex relationship between antihypertensive treatments and AD pathogenesis, warranting further investigation.

Keywords:
Alzheimer's diseaseAmyloid β-proteinAngiotensin II receptor blockers

More Related Videos

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons06:23

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons

Published on: October 30, 2018

7.1K
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

17.3K

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.9K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.9K
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
2.2K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.7K